NovoCure (NVCR) Other financing activities (2018 - 2026)

NovoCure (NVCR) has reported Other financing activities for 9 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.

• Quarterly Other financing activities rose 878.09% year-over-year to $2.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.5 million (down 45.25% YoY) and the FY2025 annual result came in at $6.1 million, up 183.53% from the prior year.
• Other financing activities improved to $2.5 million in Q2 2026 per NVCR's latest filing, from $390000.0 in the prior quarter.
• Over the last five years, Other financing activities for NVCR reached as high as $5.2 million in Q1 2025 and fell as low as $77000.0 in Q4 2025.
• A 5-year average of $1.8 million and a median of $1.0 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities tumbled 95.91% — and 2025, when it jumped 2363.38%.
• Year by year, Other financing activities stood at $952000.0 in 2022, then tumbled by 60.4% to $377000.0 in 2023, then jumped by 91.51% to $722000.0 in 2024, then slumped by 89.34% to $77000.0 in 2025, then surged by 3088.31% to $2.5 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $2.5 million, $390000.0, and $77000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.